45例晚期非小细胞肺癌EGFR-TKIs治疗获益后出现孤立进展后联合局部治疗的回顾性分析  

Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment

作　　者：张昕[1] 王彬[1] 林琳[1] 郝学志[1] 陈闪闪[1] 李峻岭[1] 张湘茹[1] 石远凯[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院内科,抗肿瘤分子靶向药物临床研究北京市重点实验室,北京100021

出　　处：《中国肺癌杂志》2013年第10期514-518,共5页Chinese Journal of Lung Cancer

基　　金：国家"重大新药创制"科技重大专项"十一五"课题(No.2008ZX09312-020);国家"重大新药创制"科技重大专项"十二五"课题(No.2012ZX09303-012);北京市科技计划项目(No.Z111102071011001);中央保健课题(No.B2009B124)资助~~

摘　　要：背景与目的表皮生长因子受体(epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)小分子物质是EGFR敏感突变肺癌患者的主要治疗手段之一。TKIs耐药后有多种表现形式,其中包括孤立性病灶局部进展。本研究对孤立病灶进展患者后继治疗进行分析。方法回顾性研究中国医学科学院肿瘤内科45例晚期非小细胞肺癌患者接受EGFR-TKI治疗后出现孤立进展的局部治疗联合TKIs治疗。结果 45例患者中11例获得部分缓解(partial response,PR)(24%),23例患者疗效为病情稳定(stable disease,SD)(51%),11例病情进展(progressive disease,PD),局部进展后再次TKI联合局部治疗的无进展生存期(progression free survival,PFS)为5.9个月。结论在接受EGFR-TKIs治疗的非小细胞细胞肺癌患者出现孤立病灶进展后,局部治疗联合TKIs药物治疗,有可延长患者的无病生存时间。Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） are routine treatments for non-small cell lung cancer （NSCLC） with EGFR mutation. Different clinical modes can be used to treat patients with TKI resistance, one of which is solitary progression. hTe aim of this study is to analyze available treatments for patients undergoing solitary progression. Methods Clinical data of 45 patients with advanced NSCLC who received lo-cal radiotherapy combined with EGFR-TKI atfer solitary progression were reviewed and analyzed. Results Among the 45 patients, 11 showed partial response, 23 achieved stable disease state, and 11 experienced progressive disease. hTe median of progression-free survival （PFS） was 5.9 months. Conclusion Local therapies combined with EGFR-TKIs can prolong the PFS of patients with NSCLC who exhibited solitary progression during EGFR-TKI treatment.

关 键 词：肺肿瘤 表皮生长因子受体酪氨酸激酶抑制剂 孤立进展 

分 类 号：R734.2[医药卫生—肿瘤]